Adamis Pharmaceuticals Corp ADMP
We take great care to ensure that the data presented and summarized in this overview for Adamis Pharmaceuticals Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ADMP
Top Purchases
Top Sells
About ADMP
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Insider Transactions at ADMP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2023
|
Ebrahim Versi CEO |
BUY
Conversion of derivative security
|
Indirect |
729,200
+44.58%
|
-
|
|
May 25
2023
|
Jannine Versi Director |
BUY
Grant, award, or other acquisition
|
Indirect |
177,194
+50.0%
|
-
|
|
May 25
2023
|
Meera J. Desai Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,138
+50.0%
|
-
|
|
May 25
2023
|
Ebrahim Versi CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
177,194
+50.0%
|
-
|
|
May 25
2023
|
Ebrahim Versi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,745
+50.0%
|
-
|
|
May 25
2022
|
Dennis J Phd Carlo |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+31.81%
|
-
|
|
Mar 18
2022
|
David C. Benedicto Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,603
-8.29%
|
$0
$0.61 P/Share
|
|
Mar 18
2022
|
Dennis J Phd Carlo |
SELL
Open market or private sale
|
Direct |
10,490
-3.54%
|
$0
$0.6 P/Share
|
|
Mar 18
2022
|
David J. Marguglio SVP and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,859
-4.83%
|
$0
$0.6 P/Share
|
|
Mar 18
2022
|
Ronald B. Moss Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,199
-3.9%
|
$0
$0.6 P/Share
|
|
Dec 01
2021
|
Dennis J Phd Carlo |
SELL
Open market or private sale
|
Direct |
47,870
-13.91%
|
$0
$0.78 P/Share
|
|
Dec 01
2021
|
David J. Marguglio SVP and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,757
-16.4%
|
$0
$0.78 P/Share
|
|
Dec 01
2021
|
Ronald B. Moss Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
35,553
-14.47%
|
$0
$0.78 P/Share
|
|
Dec 01
2021
|
David C. Benedicto Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,554
-23.77%
|
$0
$0.78 P/Share
|
|
Feb 21
2021
|
Dennis J Phd Carlo |
BUY
Exercise of conversion of derivative security
|
Direct |
27,822
+7.48%
|
-
|
|
Feb 21
2021
|
Ronald B. Moss Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,911
+5.36%
|
-
|
|
Feb 21
2021
|
David J. Marguglio SVP and Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,258
+6.71%
|
-
|
|
Feb 21
2021
|
Robert O Hopkins Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,258
+7.44%
|
-
|
|
Nov 20
2020
|
Robert O Hopkins Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
35,000
-12.08%
|
$0
$0.41 P/Share
|
|
Nov 20
2020
|
David J. Marguglio SVP and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
35,000
-10.86%
|
$0
$0.4 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 729K shares |
|---|